On Thursday, Shares of Barrick Gold Corporation (USA) (NYSE:ABX), gained 0.08% to $12.44.
Barrick Gold Corporation, declared that Dr. David Naylor has elected to leave the company’s Board of Directors in order to focus on the resumption of his academic duties on a full-time basis.
“We thank David for his valuable contributions to Barrick, and wish him well in his future endeavors,” said Barrick Chairman John L. Thornton.
Barrick Gold Corporation produces and sells gold and copper. The company is also involved in exploration and mine development activities. It conducts mining, development and exploration, and other activities in various countries, counting the United States, Canada, Australia, Argentina, Chile, Peru, the Dominican Republic, Papua New Guinea, Tanzania, Zambia, and Saudi Arabia.
Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), declined -2.32% to $8.84, during its last trading session.
Ariad Pharmaceuticals, declared that it will present at the Jefferies 2015 Global Healthcare Conference being held in New York City. Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will provide an overview of the Company’s business on Thursday, June 4, 2015 at 1:00 p.m. (ET).
The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at http://www.ariad.com/investor. A replay of the presentation will also be accessible and archived on the site for three weeks.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
At the end of Thursday’s trade, Shares of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), gained 12.22 % to $ 3.03.
Actinium Pharmaceuticals, Inc., declared the forthcoming poster and abstract at ASCO 2015, the 51st Annual Meeting of American Society of Clinical Oncology, to be held in Chicago on May
29 - June 2. Data will be presented from the Company’s ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients.
Clinical data from the first three cohorts will be discussed. Cohort 3, which comprised of 3 additional patients, demonstrated no dose limiting toxicities in patients older than 60 and up to 87 years of age who were not eligible for presently approved therapies. Two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery (CRi). These responses were documented in the settings of high pre-treatment leukemia burdens of up to 88% in the bone marrow. In the previous cohort treated at a lower dose level of Actimab-A, one patient achieved CRi. The Company also recently declared that it began the fourth and last cohort (2.0 μCi/kg per dose) in the Phase I portion of this trial.
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies.
Finally, Murphy Oil Corporation (NYSE:MUR), ended its last trade with 0.76% gained, and closed at $ 43.47.
Murphy Oil Corporation, declared that Roger Jenkins, President and CEO, will present at Bernstein`s 31st Annual Planned Decisions Conference on Friday, May 29, 2015 at 8:00 a.m. EDT.
Murphy Oil Corporation is an independent exploration and production company with a strong, oil-weighted portfolio of global offshore and onshore assets. Exploration activities are focused in four main regions: Deepwater Gulf of Mexico, the Atlantic Margin, Southeast Asia and Australia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
